SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Melatonin	DSIP (Emideltide)	Melanotan II
Research Topic	Neuro / Cognitive Research	Neuro / Cognitive Research	Tissue / Repair Research
Pharmacology	Endogenous circadian hormone / formulation-specific medicine	Experimental nonapeptide historically studied in sleep and neuroendocrine research	Experimental cyclic melanocortin peptide
PrimeCore Class	Class AApproved in a bounded context	Class CExperimental / limited evidence	Class CExperimental / limited evidence
Evidence Grade	Grade AStrong regulatory + clinical evidence	Grade CEarly human evidence	Grade CEarly human evidence
Evidence boundary	Melatonin is a circadian hormone, not Melanotan. EU-authorised Circadin concerns short-term primary insomnia in adults aged 55 or over and uses a prolonged-release formulation. Modest sleep benefits cannot be transferred to every supplement, age group or injection. Drowsiness and interactions require attention.	A peptide associated with sleep research, but identity, study quality and clinical evidence remain limited and uncertain.	Melanotan II is distinct from afamelanotide and bremelanotide. TGA's 17 August 2026 advisory found inconsistent content in tested nasal products and states there are no authorised Melanotan II products in Australia. FDA lists serious case reports and impurity/immunogenicity concerns; these do not quantify causality or universal incidence.
Unknowns	Insufficient data in the current dataset	confirmed endogenous gene, precursor, receptor and physiological role human pharmacokinetics and bioavailability across proposed routes long-term safety, immunogenicity, reproductive safety and rare adverse events clinically meaningful benefit in modern insomnia populations efficacy for narcolepsy or opioid withdrawal current product-specific regulatory status outside the reviewed FDA compounding process	Insufficient data in the current dataset
Limitations	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) Melatonin ≠ Melanotan; ผลเรื่องการนอนไม่เท่ากับยืดอายุ รักษามะเร็ง หรือรับรองการฉีด	The human literature is old, small and predominantly intravenous, while current commercial discussion often concerns other routes. Positive studies used few participants; the 16-person chronic-insomnia trial found weak and inconsistent effects. The endogenous identity and receptor remain unresolved. FDA also found route mismatch, naming complexity, insufficient effectiveness and limited safety information.	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) ประโยชน์ของยาที่ออกฤทธิ์ melanocortin ตัวอื่นไม่โอนไป Melanotan II; Grade C ไม่ใช่คำรับรอง cosmetic use
Sources	EMA · Circadin clinical assessment	https://pertento.fda.moph.go.th/fda_search_drug/SEARCH_DRUG/FRM_SEARCH_DRUG.aspx https://www.accessdata.fda.gov/scripts/cder/daf/ https://www.ema.europa.eu/en/medicines https://www.fda.gov/media/193344/download https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks https://precision.fda.gov/uniisearch/srs/unii/YN28Z5YZ73 https://pubmed.ncbi.nlm.nih.gov/6895513/ https://pubmed.ncbi.nlm.nih.gov/6112579/ https://pubmed.ncbi.nlm.nih.gov/1299794/ https://pubmed.ncbi.nlm.nih.gov/2554357/ https://pubmed.ncbi.nlm.nih.gov/568769/ https://pubmed.ncbi.nlm.nih.gov/590449/ https://pubmed.ncbi.nlm.nih.gov/16539679/ https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list https://products.mhra.gov.uk/	FDA · significant compounding safety risks; Melanotan II entry Pilot phase I · PMID 8637402 TGA laboratory safety advisory · 17 August 2026
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.